BFEC
KDNY

Benjamin F. Edwards & Company’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Benjamin F. Edwards & Company’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-11
Closed – – 2004
2019
Q2 		$0 Hold
11
– – ﹤0.01% 1990
2019
Q1 		$0 Buy
+11
New +$192 ﹤0.01% 1792

Other funds holding KDNY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Benjamin F. Edwards & Company's KDNY Position: Q3 2019 in Review

Benjamin F. Edwards & Company sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2019, closing a stake of 11 shares.

Benjamin F. Edwards & Company first reported a position in KDNY in Q1 2019 and held it in 2 quarters. The position peaked at $0 in Q2 2019. 88 funds tracked by Wall St. Rank hold KDNY as of Q3 2019.

  • Benjamin F. Edwards & Company reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Benjamin F. Edwards & Company sold 11 Chinook Therapeutics, Inc. Common Stock shares in Q3 2019.
  • Benjamin F. Edwards & Company first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2019 and held it in 2 quarters.
  • Benjamin F. Edwards & Company's Chinook Therapeutics, Inc. Common Stock position peaked at $0 in Q2 2019.
  • 88 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2019.

Based on Benjamin F. Edwards & Company's 13F filing for Q3 2019, filed 5 Nov 2019.